Research Analysts Offer Predictions for BIO Q3 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research cut their Q3 2025 earnings estimates for Bio-Rad Laboratories in a research report issued on Thursday, March 6th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.72 per share for the quarter, down from their prior forecast of $2.94. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.09 EPS, Q4 2026 earnings at $3.22 EPS, FY2026 earnings at $12.34 EPS and FY2027 earnings at $9.27 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Trading Up 1.1 %

Shares of NYSE:BIO opened at $260.92 on Friday. The stock has a 50 day moving average of $321.12 and a 200 day moving average of $330.63. The company has a market cap of $7.31 billion, a PE ratio of -4.01 and a beta of 0.98. Bio-Rad Laboratories has a 12-month low of $248.22 and a 12-month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Bio-Rad Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in Bio-Rad Laboratories by 58.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 872 shares of the medical research company’s stock worth $292,000 after purchasing an additional 322 shares in the last quarter. Amalgamated Bank lifted its position in shares of Bio-Rad Laboratories by 119.7% in the third quarter. Amalgamated Bank now owns 9,033 shares of the medical research company’s stock worth $3,022,000 after buying an additional 4,921 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after buying an additional 21,669 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in Bio-Rad Laboratories by 10.2% during the third quarter. Kornitzer Capital Management Inc. KS now owns 38,517 shares of the medical research company’s stock valued at $12,887,000 after buying an additional 3,564 shares during the last quarter. Finally, Rovin Capital UT ADV purchased a new position in Bio-Rad Laboratories during the 3rd quarter valued at approximately $669,000. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.